Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Diana Dawson
Regulatory Coordinator II
Cancer Center Division
Overview
Research
More
Collaboration
(19)
Rachna Shroff
Mutual work: 13 Grants﹒18 Proposals
Collaboration Details
Abhijeet Kumar
Mutual work: 1 Proposal﹒1 Grant
Collaboration Details
Michele Chu-Pilli
Mutual work: 1 Grant
Collaboration Details
Hina Arif Tiwari
Mutual work: 7 Grants﹒9 Proposals
Collaboration Details
Umbreen Rozell
Mutual work: 4 Proposals﹒4 Grants
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(15)
A Phase 1/2 Open-Label, Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Gastroesophageal Cancer: Master (KE
Active
·
2024
·
$0 / $4.5M
·
External
cancer,
immunotherapy,
clinical trial,
chemotherapy,
treatment
A Phase 1b/2a, Double-Blind, Placebo-Controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV)
Active
·
2024
·
$0 / $635.9K
·
External
clinical trials,
drug therapy,
pharmacology,
medical research,
therapeutic interventions
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active
·
2024
·
$0 / $548.6K
·
External
oncology,
clinical trials,
chemotherapy,
cancer treatment,
drug combination
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/
Active
·
2024
·
$0 / $434.6K
·
External
clinical trials,
cancer treatment,
drug efficacy,
therapeutic intervention,
precision medicine
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $825.5K
·
External
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
Page 1 of 3
Previous page
Next page
